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Abstract
OBJECTIVE: To assess the efficacy and safety of
Sancai powder in patients with type 2 diabetes mel-
litus (T2DM) inadequately controlled with single
oral metformin in a randomized controlled trial
(RCT).
METHODS: A total of 132 patients with T2DM were
enrolled in the study, who only took metfor-
min (500-1000 mg/day) for at least three months
and with inadequate glycemic control (7.0% ≤ he-
moglobin A1c ≤ 9.0% ) in the past three months.
The patients stopped taking metformin with life-
style interventions for three weeks, and 105 pa-
tients qualified for the program. They were random-
ly divided into the Sancai powder group and the
metformin group (1500 mg/day). The follow-up pe-
riod was for 12 weeks. Comparisons of several vari-
ables were analyzed.
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RESULTS: No significant differences were found be-
tween the two groups in hemoglobin A1c (HbA1c),
fasting plasma glucose (FPG) and 2 h post-meal glu-
cose (2hPG), although they had decreased signifi-
cantly (P < 0.01). Homeostasis model assessment of
beta cell function index was significantly im-
proved in Sancai powder group (P < 0.01), and
there were significant differences in the changes of
homeostasis model assessment of insulin resis-
tance and insulin sensitivity index in the two
groups (P < 0.05). Sancai powder significantly re-
duced triglyceride level (P < 0.05), although there
was no significant difference in the body weight
and body mass index in the two groups.
CONCLUSION: In this 12-week study, Sancai pow-
der could significantly reduce hemoglobin A1c,
FPG and 2hPG levels, improved beta-cell function
and insulin resistance of the T2DM inadequately
controlled with metformin.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Diabetes mellitus (DM) is a metabolic disease charac-
terized by hyperglycemia as a result of insulin resis-
tance (IR) and beta-cell failure, described as "Xiaoke"
in Huang Di Nei Jing1 in Traditional Chinese Medicine
(TCM). The population with diabetes is expected to
rise to 439 million.2 Large-scale epidemiological studies
have reported that the estimated prevalence of diabetes
in China was 11.6%. Therefore, these findings indicate
the importance of diabetes as a public health problem
in China.3
TCM plays an important role in Chinese health care
system,4 which has advantages in preventing and treat-
ing DM, and promotes clinical, scientific research and
the development of new drugs, such as Xiaoke Pill (a
preparation widely used for diabetes, which contains
Chinese herbal medicine and glibenclamide). It can im-
prove the symptoms of diabetes, and has reduction of
hypoglycemia risk in diabetes patients.5 Meanwhile,
Chinese herbal medicine Huanglian (Rhizoma Copti-
dis) has great effects in lowering blood glucose, reliev-
ing IR and protecting the function of beta-cell.6 Some
studies report that the TCM formula "Fructus Mume"
can significantly decrease the fasting and postprandial
glucose levels of DM.7
Sancai powder formula was created on the basis of
three ancient TCM formulas-''San Cai Tang'', Jiao Tai
Wan and Fructus Mume The selection of those Chi-
nese herbal medicines for the treatment of diabetes was
based on theory of TCM. San Cai, contains three herb-
al medicine, Tiandong (Radix Asparagi Cochinchinen-
sis), Renshen (Radix Ginseng), Dihuang (Rhizoma
Rehmanniae) (heaven, earth and human), and has been
used to tonify Qi and Yin in terms of TCM theory.
The preliminary study of our research showed that San-
cai powder had the effect of lowering blood sugar,
moreover, a single-blind randomized controlled trial
was conducted by our team to approve that Sancai
powder could effectively improve endothelial dysfunc-
tion (ED), insulin resistance (IR), hyperinsulinemia,
and the symptoms of mild vascular dementia (VaD).8
Therefore, this study was conducted to access the effica-
cy and safety of Sancai powder with the comparison of
single oral metformin, which was a first-line anti-dia-
betic drug applied widely in clinical study.
MATERIALS ANDMETHODS
Study design
A single-blind randomized controlled trial (RCT) was
conducted, and with patients blind to the drug condi-
tions. Trial evaluators were formally trained physicians.
Randomization was undertaken by a computer using
random number tables for each condition. Allocation
of treatment conditions was known to the physicians
and nurses who physically administered the drugs to
the patients. Sample size was calculated by an inspec-
tion level where α = 0.05, the power of a test was 0.80,δ = 10%, and the losing ratio was 10%.
This was a multi-centered, randomized controlled trial,
including the screening period, washout period (3
weeks) and follow-up period (12 weeks, follow-up at
every 2 weeks). Patients who met the criteria (tak-
ing only metformin (500-1000 mg/day) for at least
three months, and [7.0% ≤ hemoglobin A1c
(HbA1c) ≤ 9.0% ] were allowed to enter the washout
period. During the washout period, patients stopped
taking diabetes drug, and received guidance of diet and
exercise according to the 2010 China Type 2 Diabetes
Clinical Practice Guidelines.9 At the end of the wash-
out period, patients still met the inclusion criteria were
randomized into the Sancai powder group and the met-
formin group. Metformin, was used as the control
drugs because of its positive safety and efficacy.
Subjects
This trial was sponsored by the Teaching Hospital of
Chengdu University of Traditional Chinese Medicine
and conducted at 7 centers in Sichuan province, Chi-
na. This research study was approved by the Institu-
tional Review Board of the Teaching Hospital of
Chengdu University of Traditional Chinese Medicine,
with all patients and/or their guardians giving signed
informed consent. Trial Registration: Chinese Clinical
641
JTCM |www. journaltcm. com October 15, 2016 |Volume 36 | Issue 5 |
Guo Q et al. / Clinical Study
Trial Register number (ChiCTR-TRC-13003368).
The other collaborated hospitals were the Center Hosp-
tial of Guangyuan City, the First People's Hosptial of
Neijiang City, Zizhong Hospital of Traditional Chinese
Medicine, the Second People's Hospital of Leshan
City, Xichang Hospital of Traditional Chinese Medi-
cine, the Integrated Traditional Chinese Medicine and
Western Medicine of Liangshan State.
Inclusion criteria
The inclusion criteria were as follows: all patients were
type 2 diabetes mellitus (T2DM) and recruited from
the out-patients department of each collaborated hospi-
tal. They all met the WHO diagnostic criteria of diabe-
tes (1999),10 7.0 mmol/L (126 mg/dL) ≤ fasting plas-
ma glucose (FPG) or 11.1 mmol/L (200 mg/dL) ≤
postprandial plasma glucose (PPG) or 2 h plasma glu-
cose (2hPG) in oral glucose tolerance test (OGTT).
Other inclusion criteria included an age of 18 to 70
years, body mass index (BMI) ranged from 18.5 kg/m2
to 30 kg/m2 and they took only metformin (500 -1000
mg/day) for at least three months and their glycosylat-
ed hemoglobin ranged from 7% to 9%.
Exclusion criteria
Patients were excluded if they had any of following: a
newly diagnosed T2DM, a history of alcohol abuse, a
history of cerebrovascular accident, malignant hyper-
tension and acute coronary syndrome within the previ-
ous 12 months, pregnancy or lactation, allergic consti-
tution, or an allergic history to TCM. Other exclusion
criteria: patients who had taken medications which are
known to affect glucose metabolism within the past
three months; or had comorbidity such as chronic
heart failure, hepatic dysfunction, chronic renal failure
and mental disorders; had diseases which are known to
affect glucose metabolism such as thyroid disease and
adrenal gland disease; had participated in other clinical
trials within the past three months.
Treatment
Both groups were given lifestyle intervention according
to the 2010 China Type 2 Diabetes Clinical Practice
Guidelines.9 Patients were standardized in their diet
and exercise therapy. Sancai Powder, which consists
of Renshen (Radix Ginseng), Tiandong (Radix Asparagi
Cochinchinensis), Dihuang (Radix Rehmanniae), Huan-
glian (Rhizoma Coptidis), Rougui (Cortex Cinnamomi
Cassiae), Wumei (Fructus Mume), was prepared by Sich-
uan New Green Pharmaceutical Development Hold-
ings Ltd (Chengdu, China). It was recommended to be
taken 1/4 dose with 200 mL of boiled water, 20 min
before meals and bedtime. Metformin was purchased
from Sino-us Shanghai Squibb Pharmaceutical Co.,
Ltd. (Shanghai, China). It was recommended to be tak-
en 500 mg, three times a day, before meals. If gastroin-
testinal discomfort occurred, metformin could be tak-
en between meals or after meal. No other drugs were
used during treatment period.
Measurements
Demographic data of the patients were recorded along
with complications of DM at the beginning of study.
Anthropometric measurements and blood glucose were
measured at the screening period and each follow-up
time, and glycosylated hemoglobin was measured by
high-performance liquid chromatography at the screen-
ing period, week 0 and week 12. The OGTT was deter-
mined with glucose oxidase method and the levels of
insulin were measured by the electrochemilumines-
cence method with a Cobas e601 analyzer (Roche Di-
agnostics Ltd., Basel, Switzerland) at week 0 and week
12. Lipids and other blood chemical tests were per-
formed by Hitachi 7170A automatic biochemical ana-
lyzer (Kabushiki Kaisha Hitachi high-tech companies,
Tokyo, Japan). Liver and kidney function, blood cell
count, urine routine and electrocardiograms were mea-
sured at week 0 and week 12. The indexes of homeosta-
sis model assessment were calculated using following
formulas: homeostasis model assessment of beta cell
function index (HOMA-β) = [20 × fasting insulin
(FIns)]/(FPG - 3.5), homeostasis model assessment of
insulin resistance (HOMA-IR) = (FPG × FIns) / 22.5,
insulin sensitivity index (ISI) = 1/ (FPG × FIns).
Statistical analysis
SPSS 19.0 was used for randomization and data analy-
sis (Boyi Consultant Information Technology Compa-
ny, Beijing, China). Normally distributed data was pre-
sented as the mean ±standard deviation ( xˉ ± s). The
measurement data analyzed with the full-analysis-set
(FAS) and compared by analysis of variance and t-test.
Statistical significance level was set at P less than 0.05.
RESULTS
Baseline characteristics
Totally 105 cases of type 2 DM were preliminarily se-
lected. Reasons for withdrawal during enrollment were
as follows. Nine cases discontinued before treatment; 4
cases from the Sancai powder group, and 5 cases from
the metformin group. Thereafter, 96 cases were ran-
domly divided into two groups, with 47 cases assigned
to the Sancai powder group and 49 cases to the control
group. In total, 96 patients completed the study.
Screening, randomization and follow-up are depicted
in Figure 1 in present study. There were no significant
differences in the baseline characteristics of the two
groups of patients (P > 0.05, Table 1).
HbA1c and plasma glucose
The level of HbA1c (Table 2) decreased from 7.91%
to 7.18% in the Sancai powder group and decreased
from 7.82% to 7.07% in the metformin group at week
12 (P < 0.01). In the Sancai powder group, the
FPG decreased by 1.46 mmol/L and the PPG de-
creased by 4.91 mmol/L after treatment (P < 0.01). In
the metformin group, FPG decreased by 1.49 mmol/L
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and the PPG decreased by 3.72 mmol/L (P < 0.01). As
a result, there were no significant differences be-
tween the two groups after treatment (P > 0.05). The
changes of FPG and PPG from baseline to week 12
can be seen in Table 3 and Figures 2 and 3.
Body weight and lipid profiles
Although the patients took medicine and lifestyle inter-
vention, the changes of body weight and body mass in-
dex were similar in the two groups during 12 weeks pe-
riod (P > 0.05, Table 2). The TG (triglyceride) de-
creased from 2.09 to 1.68 mmol/L in the Sancai pow-
der group (P < 0.05), there were significant differences
compared with the metformin group (P < 0.05). More-
over, there were no significant differences in lipid in
the two groups.
Oral glucose tolerance test and insulin releasing test
After 12 weeks, the levels of plasma glucose and insulin
in the OGTT and the insulin releasing test had
changed in the two groups (Table 2 and Figures 4 and
5). In the Sancai powder group, plasma glucose levels
of OGTT at 0 h, 1 h, and 2 h decreased significant-
ly (P < 0.01), and the change of 3hPG was significant-
ly different compared with baseline (P < 0.05). The in-
sulin levels changed significantly at 1 h, 2 h, and 3 h,
excluded 0 h, especially the increase of 1 h and de-
crease of 3 h were significantly different compared with
the metformin group (P < 0.01 or P < 0.05). In the
metformin group, the plasma glucose levels at 0 h, 1
h, and 3 h and the insulin at 3 h changed significantly
(P < 0.05).
Indexes of homeostasis model assessment
There were significant differences in the increase of
HOMA-β in the Sancai group (P < 0.01). The chang-
es of HOMA-IR and ISI were significant in both
groups (P < 0.05, Table 2). There were no significant
differences in all indexes between two groups after
treatment (P > 0.05).
Evaluation of safety
During the 12 weeks period, 1 patient suffered from di-
arrhea and abdominal distension for withdrawal in the
Sancai powder group. The symptoms disappeared after
stopping taking Sancai powder. In the metformin
group, 5 patients suffered from mild and transient gas-
trointestinal symptoms. Compared with the baseline,
there were no significant differences in liver and kidney
function and other safety indicators in the two groups
(P > 0.05, Table 2).
DISCUSSION
In this study, we have found that the Sancai powder
was as effective as metformin in reducing plasma glu-
cose levels and glycosylated hemoglobin; HbA1c de-
creased by 0.73% in the Sancai powder group, and
metformin decreased by 0.75%. Initially, type 2 diabet-
ic patients inadequately controlled with oral hypoglyce-
mic drugs singly, which have poorly controlled blood
glucose levels, are the enhancive difficulty of trials. Nev-
ertheless, there are good curative effects achieved in the
two groups. Moreover, our study had suggested
that Sancai powder had no obvious correlation with
the original body weight and effect in reducing blood
glucose, this was the difference compared with metfor-
min,12 therefore, patients with normal body mass index
and overweight patients were included in the trial.
Some studies had found that metformin taken 1.5 g/
day was appropriate and effective for Asian people,
which was effective in reducing weight, regulating lipid
metabolism and improving insulin sensitivity. The indi-
ces including body weight, lipid profiles and homeo-
stasis model assessment were measured and analyzed in
the two groups. We expected to find the possible mech-
anism of Sancai powder.
After one week, FPG and PPG had decreased signifi-
cantly in the both groups. Insulin secretagogue or al-
pha glucosidase inhibitors could decrease postprandial
Screened (n = 132) Eliminated (n = 27)
11 did not conform to this standard
7 withdrew consent
6 violated program
3 lost to flollow-up
Enrolled (n = 105)
Sancai powder (n = 51) Metformin (n = 54)
Discontinued (n = 4)
1 violated program
2 lost to follow-up
1 adverse reactions
Discontinued (n = 5)
2 violated program
2 withdrew consent
1 lost to follow-up
Completed study (n = 47) Completed study (n = 49)
Figure 1 Flow diagram
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blood glucose level in short-term, which raised a ques-
tion that how the mechanism of Chinese medicine
works on decreasing postprandial blood glucose in short
time. Study showed that Huanglian (Rhizoma Copti-
dis) could stimulate the release of GLP-1 to increase in-
sulin level and the effective reduction of the postprandi-
al blood glucose.13 Berberine also could relieve insulin
resistance and inhibit gluconeogenesis.14 Some stud-
Table 1 Baseline characteristics of patients in the two groups ( xˉ ± s)
Characteristic
Sex (n)
Age (year)
Diabetes duration (month)
Body weight (kg)
BMI (kg/m2)
HbA1c (%)
FPG (mmol/L)
2hPG (mmol/L)
TC (mmol/L)
TG (mmol/L)
HDL (mmol/L)
LDL (mmol/L)
OGTT 0 h (mmol/L)
OGTT 1 h (mmol/L)
OGTT 2 h (mmol/L)
OGTT 3 h (mmol/L)
Insulin 0 h (mU/L)
Insulin 1 h (mU/L)
Insulin 2 h (mU/L)
Insulin 3 h (mU/L)
Ln [HOMA-IR]
Ln [ISI]
Ln [HOMA-β]
ALT (U/L)
AST (U/L)
SCr (umol/L)
BUN (mmol/L)
SUA (umol/L)
WBC (1×109/L)
RBC (1×1012/L)
Hb (g/L)
PLT (1×109/L)
male
female
Sancai powder group
29
22
52.0±9.7
18.9±15.3
62.8±8.5
23.8±2.1
7.9±0.7
9.1±2.0
15.5±3.5
4.7±0.9
2.1±1.3
1.2±0.3
2.8±0.7
9.1±2.5
16.3±4.2
15.4±4.0
12.8±4.3
7.9±3.2
26.4±12.1
24.6±11.5
16.5±5.3
1.1±0.4
－4.3±0.5
3.2±0.6
20.9±9.5
23.7±7.1
58.4±12.6
5.4±1.5
277.5±71.7
5.6±0.8
4.3±0.5
134.2±15.6
175.4±50.5
Metformin group
21
33
53.7±9.4
15.6±14.7
63.9±9.1
24.5±2.0
7.8±0.7
8.7±1.7
14.8±3.2
4.8±0.9
2.2±1.4
1.3±0.3
2.9±0.8
8.9±2.4
15.4±4.5
14.7±3.5
12.6±3.6
7.5±3.8
24.2±13.2
25.1±12.4
18.1±6.8
1.0±0.5
－4.2±0.5
3.4±0.6
21.8±8.9
22.8±8.7
60.2±14.8
5.2±1.3
298.3±65.2
5.5±0.8
4.3±0.5
132.5±17.2
178.5±49.3
P value
0.07
0.36
0.36
0.52
0.18
0.39
0.21
0.29
0.52
0.72
0.11
0.75
0.48
0.41
0.46
0.69
0.57
0.43
0.82
0.18
0.15
0.47
0.11
0.56
0.54
0.41
0.54
0.21
0.63
0.73
0.49
0.51
Notes: sancai powder group: the treatment group; metformin group: the control group. Patients in the treatment group were treated with
Sancai powder. Patients in the control group were treated with metformin alone. BMI: body mass index; HbA1c: Hemoglobin A1C; FPG:
fasting plasma glucose; 2hPG: 2h plasma glucose; TC: total cholesterol; TG: triglyceride; HDL: high density lipoprotein; LDL: low density
lipoprotein; OGTT: oral glucose tolerance test; HOMA-IR: homeostasis model assessment of insulin resistance; ISI: insulin sensitivity in-
dex; HOMA-β: homeostasis model of assessment for beta cell function index; ALT: alanine aminotransferase; AST: aspartate amino trans-
ferase; SCr: serum creatinine; BUN: blood urea nitrogen; SUA: serum uric acid; WBC: white blood cell; RBC: red blood cell; Hb: hemo-
globin; PLT: platelet.
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ies showed that Rougui (Cortex Cinnamomi Cassiae)
could decrease blood glucose.15 Study had found
that Rougui (Cortex Cinnamomi Cassiae) decoc-
tion could inhibit the activity of alpha glucosi-
dase and delay the peak of postprandial blood glucose
in animal experiments.16 Moreover, Dihuang (Radix
Rehmanniae) could inhibit gluconeogenesis to reduce
fasting blood glucose in diabetic rats.17 Many previ-
ous studies has shown that a lot of traditional Chinese
herbs have no direct anti-diabetic effect, which are ef-
Table 3 Changes in FPG and PPG (mmol/L, xˉ ± s)
Indicator
FPG
PPG
Sancai powder group
Metformin group
Sancai powder group
Metformin group
Week 0
9.1±2.0
8.7±1.7
15.5±3.5
14.8±3.2
Week 4
8.3±1.7a
8.2±1.6
12.3±2.8b
12.2±2.8b
Week 8
7.8±1.5b
7.7±1.6b
11.0±2.7b
11.5±2.7b
Week 12
7.5±1.5b
7.2±1.5b
10.6±2.3b
11.1±2.1b
Notes: Sancai powder group: the treatment group; metformin group: the control group. Patients in the treatment group were treated with
Sancai powder. Patients in the control group were treated with metformin alone. FPG: fasting plasma glucose; PPG: postprandial plasma
glucose. Compared with pre-treatment figures in the same group, aP < 0.05; compared with those pre-treatment figures in the same group,
bP < 0.01.
Table 2 Changes in indicators in the two groups ( xˉ ± s)
Characteristic
HbA1c (%)
TC (mmol/L)
TG (mmol/L)
LDL (mmol/L)
HDL (mmol/L)
Body weight (kg)
BMI (kg/m2)
OGTT 0 h (mmol/L)
OGTT 1 h (mmol/L)
OGTT 2 h (mmol/L)
OGTT 3 h (mmol/L)
Insulin 0 h (mU/L)
Insulin 1 h (mU/L)
Insulin 2 h (mU/L)
Insulin 3 h (mU/L)
Ln [HOMA-IR]
Ln [HOMA-β]
Ln [ISI]
ALT (U/L)
AST (U/L)
Crea (umol/L)
BUN (mmol/L)
UA (umol/L)
WBC (1×109/L)
RBC (1×1012/L)
Hb (g/L)
PLT (1×109/L)
Sancai powder group
7.2±0.5b
4.5±0.8
1.7±0.8ac
2.5±0.7
1.2±0.3
61.5±7.1
23.3±2.0
7.8±2.0b
13.3±3.7b
12.1±3.3b
10.5±3.2a
7.8±3.0
34.9±11.3bd
31.0±10.8a
13.7±5.5ac
0.8±0.5a
3.6±0.5b
-4.1±0.5a
21.5±9.4
22.6±7.4
55.1±14.5
5.1±1.4
275.6±75.5
5.6±0.8
4.3±0.6
135.4±16.3
178.7±54.7
Metformin group
7.1±0.6b
4.7±0.8
2.1±1.2
2.7±0.7
1.2±0.3
62.2±8.5
23.8±2.0
7.7±2.4a
13.5±3.5a
13.7±4.1
10.6±3.8a
6.2±3.6
27.4±13.6
27.1±11.9
16.9±5.7
0.7±0.5a
3.6±0.7
－4.0±0.5a
20.4±9.5
21.7±8.5
57.2±13.7
5.3±1.2
291.3±79.4
5.5±0.8
4.3±0.5
134.6±14.4
181.5±43.5
Notes: sancai powder group: the treatment group; metformin group: the control group. Patients in the treatment group were treated with
Sancai powder. Patients in the control group were treated with metformin alone; BMI: Body Mass Index; HbA1c: Hemoglobin A1C; FPG:
fasting plasma glucose; 2hPG: 2h plasma glucose; TC: total cholesterol; TG: triglyceride; HDL: high density lipoprotein; LDL: low density
lipoprotein; OGTT: oral glucose tolerance test; HOMA-IR: homeostasis model assessment of insulin resistance; ISI: insulin sensitivity in-
dex; HOMA-β: homeostasis model of assessment for beta cell function index; ALT: alanine aminotransferase; AST: aspartate amino trans-
ferase; SCr: serum creatinine; BUN: blood urea nitrogen; SUA: serum uric acid; WBC: white blood cell; RBC: red blood cell; Hb: hemo-
globin; PLT: platelet. Statistical significance between figures compared with pre-treatment figures in the same group is aP < 0.05. Com-
pared with those pre-treatment figures in the same group is bP < 0.01; compared with the metformin group, cP < 0.05; compared with the
metformin group, dP < 0.01.
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fective to decrease blood glucose level because of an-
ti-inflammatory, improving the function of β-cell, in-
creasing insulin sensitivity and other ways.18 For in-
stance, ginseng extract can up-regulate the AMP acti-
vated protein kinase (AMPK) and its target molecule
level along with glucose transporter 4 (GLUT4) to re-
lieve insulin resistance in diabetes mouse models, which
in turn lower blood glucose and lipid levels.19 These may
be the possible mechanisms of some ingredients of San-
cai formula in reducing blood glucose.
As we know, compared with other anti-diabetic drugs,
metformin has a unique advantage in reducing weight
and fat. By the same foundation therapy of diet and ex-
ercise, the average weight of the metformin group re-
duced by 1.69 kg, while there were no significant dif-
ferences in the changes of blood lipids. On the con-
trary, compared with baseline levels, there was signifi-
cant difference in the decrease of TG levels in the San-
cai powder group (P < 0.05). Study reported that Rou-
gui (Cortex Cinnamomi Cassiae) extract can effectively
reduce the HbA1c and TG levels of DM.20 Another
study found that Huanglian (Rhizoma Coptidis) and Di-
huang (Radix rehmannia) root decoction can effectively
relieve hyperglycemia, hypertriglyceridemia and hyper-
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cholesterolemia in diabetes rats.21 While metformin reg-
ulates the lipids, which is based on reducing body
weight, waist circumference and intake of calories in
patients. Undoubtedly, there is insufficient evidence
that metformin could lower blood lipids directly.
The figure 5 showed that the insulin releasing curve was
changed closely to physiological curve in the San-
cai powder group after treatment. The average insulin
levels at 1 h and 2 h increased by 8.75 and 6.47mU/L re-
spectively, while it decreased 2.82 mU/L at 3 h in the
Sancai powder group. Meanwhile, the correspond-
ing results of OGTT also have more significant chang-
es compared with those in the metformin group. It
showed that Sancai powder has great effect on improv-
ing beta-cell function in diabetes because of the in-
creased HOMA- β (P < 0.01). Study reported that ber-
berine activated AMPK to inhibit insulin gene promot-
er, which played a protective role of pancreatic beta-
cell.22 Berberine and Rougui (Cortex Cinnamomi Cassi-
ae) could increase SOD (superoxide dismutase) activity
and decrease MDA (malonaldehyde) level to reduce
blood glucose in diabetic rats induced by alloxan and
streptozotocin.23,24 There is an unavoidable truth that
increased HOMA-β was closely related to recovery of
beta-cell function because of the relieve of glucose
toxicity.
During the follow-up period, there was no severe hypo-
glycemia in the two groups. Drug-induced hypoglyce-
mia could often be found in patients who use insulin
or insulin secretagogues. Chinese herbal medicine based
on multiple targets could decrease blood glucose and
parts of them have anti-hypoglycemia effect, which en-
sures the safety of TCM in glycemic control. At pres-
ent, compared with glibenclamide, it was confirmed
that patients using Xiaoke pill in treatment of diabetes
could decrease the total hypoglycemia rate by 38%.5 Ani-
mal experiment reported thatDihuang (Rhizoma Rehm-
anniae) decoction could increase the level of liver glyco-
gen to prevent hypoglycemic,15 meanwhile, Chinese
herbal medicine are not associated with significant hy-
poglycemic effect in health people, which have some in
common with metformin. Another experiment showed
that increased plasma exposures of berberine derived
from Huanglian (Rhizoma Coptidis) is caused by P-gly-
coproteindamaged in diabetic rats.25
Some studies had found that TCM was associated with
greater improvement in symptoms of diabetes and pre-
vention of complications. There exist few reports about
TCM in control of blood glucose in clinical trials. In
this study, compared with metformin, Sancai pow-
der got equivalent efficacy in decreasing blood glucose,
which is closely related to pharmacological action of
single herb, however, the essence of TCM based on the
theory is to get compatibility of herbs. Study reported
that Jiao Tai Wan regulated glucose and lipids by the
down-regulation of acetyl coenzyme A carboxylase
(ACC) and fatty acid synthase protein expressions, and
the up-regulation of AMP-activated protein kinase
(AMPK) and phosphorylated-ACC (pACC) protein ex-
pressions in the liver tissues, there is no doubt that the
mechanism of action is consistent with the TCM theo-
ry Yin-Yang.26
In conclusion, fasting and postprandial blood glu-
cose of type 2 diabetes inadequately controlled with
oral metformin singly could be effectively decreased by
Sancai powder in the short term. It also could signifi-
cantly improve the function of beta-cell and IR, and
regulate the lipids metabolism. Besides, we found that
type 2 diabetes inadequately controlled with metfor-
min singly need increase of dose to get better glycemic
control. No serious adverse event was reported during
the study. However, this study lasted only 12 weeks
and further studies should be warranted to confirm its
long-term efficacy and safety in the treatment of DM.
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